 Kristen Miller
Concepts (309)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antimicrobial Stewardship | 2 | 2017 | 96 | 1.040 |
Why?
| | Sleep Apnea, Obstructive | 3 | 2021 | 234 | 1.010 |
Why?
| | Burns | 2 | 2018 | 247 | 1.010 |
Why?
| | Hematopoietic Stem Cell Transplantation | 4 | 2021 | 540 | 1.000 |
Why?
| | Child | 37 | 2024 | 19137 | 0.960 |
Why?
| | Child, Preschool | 20 | 2021 | 9493 | 0.950 |
Why?
| | Communicable Disease Control | 2 | 2021 | 72 | 0.930 |
Why?
| | Tonsillectomy | 2 | 2021 | 81 | 0.910 |
Why?
| | Infant | 18 | 2022 | 8295 | 0.880 |
Why?
| | Attitude of Health Personnel | 2 | 2021 | 993 | 0.830 |
Why?
| | Bandages | 2 | 2018 | 31 | 0.810 |
Why?
| | Tacrolimus | 4 | 2021 | 151 | 0.800 |
Why?
| | Milrinone | 1 | 2021 | 27 | 0.770 |
Why?
| | Organizational Policy | 1 | 2021 | 70 | 0.760 |
Why?
| | Intensive Care Units, Pediatric | 1 | 2021 | 157 | 0.740 |
Why?
| | Retrospective Studies | 25 | 2024 | 12990 | 0.730 |
Why?
| | Retroviridae | 1 | 2020 | 89 | 0.730 |
Why?
| | Tinnitus | 1 | 2021 | 61 | 0.730 |
Why?
| | Patient Admission | 1 | 2021 | 177 | 0.730 |
Why?
| | CD3 Complex | 1 | 2020 | 93 | 0.720 |
Why?
| | Graft Rejection | 3 | 2021 | 555 | 0.720 |
Why?
| | Hemodynamics | 3 | 2021 | 1004 | 0.720 |
Why?
| | Heart Defects, Congenital | 3 | 2021 | 703 | 0.710 |
Why?
| | Immunoassay | 1 | 2020 | 101 | 0.710 |
Why?
| | Algorithms | 4 | 2021 | 1543 | 0.710 |
Why?
| | Wound Healing | 2 | 2018 | 270 | 0.690 |
Why?
| | Communicable Diseases | 2 | 2017 | 132 | 0.670 |
Why?
| | Anatomic Landmarks | 1 | 2018 | 28 | 0.660 |
Why?
| | Abdominal Wall | 1 | 2018 | 27 | 0.660 |
Why?
| | Preoperative Care | 1 | 2021 | 332 | 0.660 |
Why?
| | Ointments | 1 | 2018 | 25 | 0.650 |
Why?
| | Casts, Surgical | 1 | 2018 | 31 | 0.650 |
Why?
| | Organ Transplantation | 1 | 2021 | 165 | 0.650 |
Why?
| | Intubation, Gastrointestinal | 1 | 2018 | 61 | 0.640 |
Why?
| | Anti-Infective Agents, Local | 1 | 2018 | 42 | 0.640 |
Why?
| | Foot Injuries | 1 | 2018 | 38 | 0.630 |
Why?
| | Hand Injuries | 1 | 2018 | 37 | 0.630 |
Why?
| | Neural Tube Defects | 1 | 2018 | 63 | 0.630 |
Why?
| | Occipital Lobe | 1 | 2017 | 23 | 0.620 |
Why?
| | Hypovolemia | 1 | 2017 | 14 | 0.620 |
Why?
| | Gastrostomy | 1 | 2018 | 93 | 0.620 |
Why?
| | Abdominal Pain | 1 | 2018 | 134 | 0.610 |
Why?
| | Extremities | 1 | 2018 | 113 | 0.610 |
Why?
| | Cancer Survivors | 1 | 2021 | 201 | 0.610 |
Why?
| | Cerebrospinal Fluid Shunts | 1 | 2017 | 31 | 0.610 |
Why?
| | Patient Selection | 1 | 2021 | 675 | 0.590 |
Why?
| | Cerebral Hemorrhage | 1 | 2017 | 100 | 0.580 |
Why?
| | Hydrocephalus | 1 | 2017 | 81 | 0.580 |
Why?
| | Adolescent | 21 | 2022 | 18483 | 0.570 |
Why?
| | Endoscopy, Gastrointestinal | 1 | 2018 | 202 | 0.570 |
Why?
| | Frontal Lobe | 1 | 2017 | 148 | 0.570 |
Why?
| | Appendicitis | 1 | 2017 | 125 | 0.560 |
Why?
| | Models, Theoretical | 2 | 2019 | 556 | 0.560 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 2020 | 634 | 0.550 |
Why?
| | Hyperglycemia | 2 | 2020 | 316 | 0.550 |
Why?
| | Spinal Cord | 1 | 2018 | 367 | 0.550 |
Why?
| | Monitoring, Physiologic | 1 | 2017 | 272 | 0.530 |
Why?
| | Hospitals, Pediatric | 3 | 2020 | 505 | 0.530 |
Why?
| | Humans | 49 | 2024 | 119032 | 0.520 |
Why?
| | Chronic Pain | 1 | 2018 | 211 | 0.510 |
Why?
| | Anti-Infective Agents | 1 | 2017 | 227 | 0.500 |
Why?
| | Male | 29 | 2021 | 57818 | 0.500 |
Why?
| | Ventricular Function, Right | 2 | 2021 | 257 | 0.500 |
Why?
| | Hodgkin Disease | 2 | 2023 | 119 | 0.500 |
Why?
| | Ultrasonography | 1 | 2018 | 716 | 0.490 |
Why?
| | Female | 29 | 2021 | 61588 | 0.480 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2020 | 985 | 0.480 |
Why?
| | Skin | 1 | 2018 | 657 | 0.470 |
Why?
| | Brain Neoplasms | 3 | 2023 | 1023 | 0.460 |
Why?
| | Practice Guidelines as Topic | 1 | 2021 | 1440 | 0.450 |
Why?
| | Substance-Related Disorders | 1 | 2021 | 971 | 0.430 |
Why?
| | Referral and Consultation | 1 | 2017 | 648 | 0.430 |
Why?
| | Infant, Newborn | 8 | 2022 | 5256 | 0.400 |
Why?
| | Heart Ventricles | 2 | 2021 | 727 | 0.400 |
Why?
| | Asthma | 2 | 2021 | 2159 | 0.400 |
Why?
| | Anaerobic Threshold | 1 | 2020 | 21 | 0.390 |
Why?
| | Adenoidectomy | 2 | 2021 | 63 | 0.380 |
Why?
| | Pulmonary Artery | 2 | 2021 | 1063 | 0.380 |
Why?
| | Respiration, Artificial | 3 | 2022 | 545 | 0.350 |
Why?
| | Forecasting | 1 | 2021 | 354 | 0.350 |
Why?
| | Pneumococcal Vaccines | 1 | 2021 | 140 | 0.350 |
Why?
| | Castleman Disease | 1 | 2019 | 14 | 0.340 |
Why?
| | Exercise Tolerance | 1 | 2020 | 233 | 0.340 |
Why?
| | Myelodysplastic Syndromes | 1 | 2020 | 119 | 0.340 |
Why?
| | Anti-Bacterial Agents | 1 | 2018 | 1517 | 0.330 |
Why?
| | Videoconferencing | 1 | 2019 | 59 | 0.330 |
Why?
| | Fontan Procedure | 1 | 2020 | 154 | 0.330 |
Why?
| | Young Adult | 9 | 2022 | 10799 | 0.320 |
Why?
| | Machine Learning | 1 | 2021 | 331 | 0.320 |
Why?
| | Tumor Burden | 1 | 2019 | 275 | 0.320 |
Why?
| | Antibody Formation | 1 | 2019 | 276 | 0.310 |
Why?
| | Transplantation Conditioning | 1 | 2019 | 156 | 0.310 |
Why?
| | Treatment Outcome | 8 | 2020 | 9346 | 0.310 |
Why?
| | Herpesviridae Infections | 1 | 2019 | 142 | 0.310 |
Why?
| | Immunoconjugates | 1 | 2018 | 89 | 0.300 |
Why?
| | Transplant Recipients | 1 | 2019 | 148 | 0.300 |
Why?
| | Carcinoma, Hepatocellular | 1 | 2019 | 227 | 0.300 |
Why?
| | Magnetic Resonance Imaging | 1 | 2018 | 3175 | 0.300 |
Why?
| | Tissue Donors | 1 | 2019 | 336 | 0.290 |
Why?
| | Continuous Positive Airway Pressure | 1 | 2017 | 57 | 0.290 |
Why?
| | Prospective Studies | 7 | 2023 | 6477 | 0.290 |
Why?
| | Glioma | 1 | 2020 | 306 | 0.290 |
Why?
| | Postoperative Complications | 1 | 2017 | 2235 | 0.280 |
Why?
| | Aftercare | 3 | 2022 | 194 | 0.280 |
Why?
| | Medication Adherence | 2 | 2020 | 556 | 0.270 |
Why?
| | Stroke Volume | 3 | 2021 | 513 | 0.270 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 2 | 2020 | 1390 | 0.260 |
Why?
| | Liver Neoplasms | 1 | 2019 | 527 | 0.250 |
Why?
| | Blood Pressure | 1 | 2021 | 1664 | 0.250 |
Why?
| | Hypoglycemia | 1 | 2019 | 401 | 0.240 |
Why?
| | Blood Glucose | 2 | 2020 | 1946 | 0.240 |
Why?
| | Growth Differentiation Factor 15 | 1 | 2024 | 35 | 0.240 |
Why?
| | Alagille Syndrome | 1 | 2024 | 37 | 0.230 |
Why?
| | Lupus Nephritis | 1 | 2024 | 55 | 0.230 |
Why?
| | Decision Making | 1 | 2020 | 809 | 0.230 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2019 | 900 | 0.230 |
Why?
| | Antineoplastic Agents | 2 | 2019 | 1974 | 0.230 |
Why?
| | Kidney Transplantation | 1 | 2019 | 585 | 0.220 |
Why?
| | Sleep | 1 | 2018 | 660 | 0.220 |
Why?
| | Health Services Accessibility | 1 | 2019 | 781 | 0.220 |
Why?
| | Follow-Up Studies | 5 | 2021 | 4596 | 0.220 |
Why?
| | Enterovirus D, Human | 1 | 2023 | 76 | 0.210 |
Why?
| | Immunosuppressive Agents | 4 | 2024 | 683 | 0.210 |
Why?
| | Lung Diseases | 1 | 2018 | 718 | 0.200 |
Why?
| | Practice Patterns, Physicians' | 1 | 2020 | 1200 | 0.200 |
Why?
| | Hyperglycinemia, Nonketotic | 1 | 2022 | 46 | 0.200 |
Why?
| | Liver Transplantation | 1 | 2019 | 847 | 0.200 |
Why?
| | Models, Biological | 1 | 2019 | 1715 | 0.200 |
Why?
| | Research | 2 | 2016 | 411 | 0.200 |
Why?
| | Survival Rate | 3 | 2020 | 1720 | 0.200 |
Why?
| | Biliary Atresia | 1 | 2024 | 224 | 0.200 |
Why?
| | Enterovirus Infections | 1 | 2023 | 164 | 0.190 |
Why?
| | Prognosis | 3 | 2020 | 3443 | 0.190 |
Why?
| | Adenosine Monophosphate | 1 | 2021 | 51 | 0.190 |
Why?
| | Isoantibodies | 1 | 2021 | 63 | 0.190 |
Why?
| | Cardiac Output, Low | 1 | 2021 | 68 | 0.190 |
Why?
| | Central Nervous System Neoplasms | 1 | 2022 | 128 | 0.190 |
Why?
| | Telemedicine | 1 | 2019 | 668 | 0.190 |
Why?
| | Adult | 9 | 2023 | 31525 | 0.180 |
Why?
| | Translations | 1 | 2020 | 17 | 0.180 |
Why?
| | Cardiotonic Agents | 1 | 2021 | 127 | 0.180 |
Why?
| | Ependymoma | 1 | 2022 | 169 | 0.180 |
Why?
| | Metered Dose Inhalers | 1 | 2020 | 18 | 0.180 |
Why?
| | Non-alcoholic Fatty Liver Disease | 1 | 2024 | 280 | 0.180 |
Why?
| | Cross-Sectional Studies | 4 | 2022 | 4552 | 0.180 |
Why?
| | Length of Stay | 2 | 2021 | 1031 | 0.180 |
Why?
| | Hybridomas | 1 | 2020 | 233 | 0.180 |
Why?
| | Insulin Resistance | 1 | 2018 | 1184 | 0.180 |
Why?
| | NFATC Transcription Factors | 1 | 2020 | 82 | 0.180 |
Why?
| | Respiratory Tract Infections | 1 | 2023 | 331 | 0.180 |
Why?
| | Genes, Reporter | 1 | 2020 | 270 | 0.170 |
Why?
| | Cardiopulmonary Bypass | 1 | 2021 | 203 | 0.170 |
Why?
| | Antibodies, Bispecific | 1 | 2019 | 33 | 0.170 |
Why?
| | Neoplasm, Residual | 1 | 2019 | 103 | 0.170 |
Why?
| | Epitopes, T-Lymphocyte | 1 | 2020 | 170 | 0.170 |
Why?
| | Foramen Magnum | 1 | 2018 | 10 | 0.170 |
Why?
| | Cystic Fibrosis | 1 | 2018 | 965 | 0.170 |
Why?
| | Genetic Vectors | 1 | 2020 | 302 | 0.170 |
Why?
| | Ilium | 1 | 2018 | 29 | 0.170 |
Why?
| | Health Care Surveys | 1 | 2021 | 546 | 0.170 |
Why?
| | Replantation | 1 | 2018 | 29 | 0.170 |
Why?
| | Perception | 1 | 2021 | 314 | 0.160 |
Why?
| | Vascular Resistance | 1 | 2019 | 356 | 0.160 |
Why?
| | Incidence | 3 | 2023 | 2424 | 0.160 |
Why?
| | Stem Cell Transplantation | 1 | 2019 | 153 | 0.160 |
Why?
| | Silver | 1 | 2018 | 27 | 0.160 |
Why?
| | Area Under Curve | 1 | 2018 | 296 | 0.160 |
Why?
| | Tibial Fractures | 1 | 2019 | 71 | 0.160 |
Why?
| | Controlled Before-After Studies | 1 | 2017 | 16 | 0.160 |
Why?
| | Drug Prescriptions | 1 | 2020 | 248 | 0.160 |
Why?
| | Spinal Fractures | 1 | 2019 | 77 | 0.160 |
Why?
| | Prevalence | 2 | 2021 | 2326 | 0.150 |
Why?
| | Heart Valve Prosthesis Implantation | 1 | 2020 | 189 | 0.150 |
Why?
| | Socioeconomic Factors | 1 | 2021 | 1129 | 0.150 |
Why?
| | Immunization | 1 | 2020 | 412 | 0.150 |
Why?
| | Sepsis | 1 | 2023 | 531 | 0.150 |
Why?
| | ROC Curve | 1 | 2018 | 473 | 0.150 |
Why?
| | Drug Utilization Review | 1 | 2017 | 60 | 0.150 |
Why?
| | Echocardiography | 1 | 2019 | 556 | 0.150 |
Why?
| | Oxygen | 1 | 2021 | 857 | 0.150 |
Why?
| | Tertiary Care Centers | 1 | 2017 | 119 | 0.150 |
Why?
| | Case-Control Studies | 2 | 2018 | 3173 | 0.150 |
Why?
| | Cardiac Catheterization | 3 | 2021 | 541 | 0.150 |
Why?
| | Severity of Illness Index | 2 | 2021 | 2674 | 0.150 |
Why?
| | Fluid Therapy | 1 | 2017 | 131 | 0.140 |
Why?
| | Drug Resistance | 1 | 2017 | 167 | 0.140 |
Why?
| | Organ Size | 1 | 2017 | 460 | 0.140 |
Why?
| | Pneumonia | 1 | 2022 | 592 | 0.140 |
Why?
| | Body Weight | 1 | 2021 | 934 | 0.140 |
Why?
| | Risk Factors | 5 | 2023 | 9003 | 0.140 |
Why?
| | Cardiac Surgical Procedures | 1 | 2021 | 461 | 0.140 |
Why?
| | Anti-Asthmatic Agents | 1 | 2020 | 343 | 0.140 |
Why?
| | Lymphocyte Activation | 1 | 2020 | 1067 | 0.140 |
Why?
| | Nutritional Status | 1 | 2018 | 300 | 0.140 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2019 | 267 | 0.140 |
Why?
| | Education, Graduate | 1 | 2016 | 36 | 0.140 |
Why?
| | Professional Competence | 1 | 2016 | 91 | 0.130 |
Why?
| | Biomarkers | 4 | 2024 | 3590 | 0.130 |
Why?
| | Patient Education as Topic | 1 | 2020 | 699 | 0.130 |
Why?
| | United States | 4 | 2024 | 12557 | 0.130 |
Why?
| | Acute Disease | 1 | 2017 | 941 | 0.130 |
Why?
| | Postoperative Period | 2 | 2021 | 309 | 0.120 |
Why?
| | Patient Readmission | 1 | 2020 | 633 | 0.120 |
Why?
| | Age Factors | 1 | 2021 | 2995 | 0.120 |
Why?
| | Obesity | 3 | 2022 | 2751 | 0.120 |
Why?
| | Colorado | 4 | 2023 | 4196 | 0.120 |
Why?
| | Diagnosis, Differential | 1 | 2018 | 1384 | 0.120 |
Why?
| | Graft Survival | 2 | 2021 | 504 | 0.120 |
Why?
| | Predictive Value of Tests | 1 | 2018 | 1868 | 0.120 |
Why?
| | Multivariate Analysis | 1 | 2017 | 1474 | 0.120 |
Why?
| | Pandemics | 1 | 2021 | 1355 | 0.110 |
Why?
| | Laboratories | 1 | 2014 | 97 | 0.110 |
Why?
| | Neuropsychological Tests | 2 | 2023 | 1032 | 0.110 |
Why?
| | Parents | 1 | 2021 | 1212 | 0.110 |
Why?
| | Biology | 1 | 2014 | 83 | 0.110 |
Why?
| | Logistic Models | 1 | 2017 | 1901 | 0.110 |
Why?
| | Athletic Injuries | 1 | 2019 | 495 | 0.110 |
Why?
| | Patient Discharge | 3 | 2022 | 794 | 0.100 |
Why?
| | Recurrence | 2 | 2019 | 975 | 0.100 |
Why?
| | Program Evaluation | 1 | 2016 | 845 | 0.100 |
Why?
| | Immunization, Secondary | 1 | 2021 | 85 | 0.100 |
Why?
| | Histocompatibility Testing | 1 | 2020 | 123 | 0.090 |
Why?
| | Cohort Studies | 2 | 2019 | 5117 | 0.090 |
Why?
| | Vinblastine | 1 | 2020 | 68 | 0.090 |
Why?
| | Anemia, Aplastic | 1 | 2020 | 30 | 0.090 |
Why?
| | Carboplatin | 1 | 2020 | 142 | 0.090 |
Why?
| | Survivors | 2 | 2023 | 418 | 0.090 |
Why?
| | HLA-DR Antigens | 1 | 2020 | 224 | 0.090 |
Why?
| | Neoplasm Grading | 1 | 2020 | 258 | 0.090 |
Why?
| | alpha-Fetoproteins | 1 | 2019 | 33 | 0.090 |
Why?
| | HLA Antigens | 1 | 2020 | 230 | 0.090 |
Why?
| | Markov Chains | 1 | 2019 | 118 | 0.080 |
Why?
| | Monte Carlo Method | 1 | 2019 | 146 | 0.080 |
Why?
| | Preoperative Period | 1 | 2019 | 110 | 0.080 |
Why?
| | Herpesvirus 8, Human | 1 | 2019 | 68 | 0.080 |
Why?
| | Hypertension, Pulmonary | 1 | 2019 | 1794 | 0.080 |
Why?
| | Time Factors | 2 | 2019 | 6414 | 0.080 |
Why?
| | Proportional Hazards Models | 1 | 2021 | 1125 | 0.080 |
Why?
| | Actigraphy | 1 | 2018 | 80 | 0.080 |
Why?
| | Exercise Test | 1 | 2020 | 551 | 0.080 |
Why?
| | Vital Capacity | 1 | 2018 | 260 | 0.080 |
Why?
| | Developmental Disabilities | 1 | 2020 | 247 | 0.080 |
Why?
| | Cannula | 1 | 2017 | 19 | 0.080 |
Why?
| | Humidity | 1 | 2017 | 45 | 0.080 |
Why?
| | Nose | 1 | 2017 | 58 | 0.080 |
Why?
| | Waiting Lists | 1 | 2019 | 228 | 0.070 |
Why?
| | Computer Simulation | 1 | 2021 | 922 | 0.070 |
Why?
| | Survival Analysis | 1 | 2020 | 1267 | 0.070 |
Why?
| | Forced Expiratory Volume | 1 | 2018 | 520 | 0.070 |
Why?
| | Polysomnography | 1 | 2017 | 157 | 0.070 |
Why?
| | Signal Transduction | 1 | 2020 | 4713 | 0.070 |
Why?
| | Heart Rate | 1 | 2020 | 729 | 0.070 |
Why?
| | Treatment Failure | 1 | 2017 | 341 | 0.070 |
Why?
| | Neoplasm Staging | 1 | 2018 | 1223 | 0.060 |
Why?
| | Patient Satisfaction | 1 | 2019 | 610 | 0.060 |
Why?
| | X-ray Repair Cross Complementing Protein 1 | 1 | 2023 | 16 | 0.060 |
Why?
| | Intelligence Tests | 1 | 2023 | 64 | 0.060 |
Why?
| | Syndecan-1 | 1 | 2023 | 30 | 0.060 |
Why?
| | Disaccharides | 1 | 2023 | 18 | 0.060 |
Why?
| | Heparitin Sulfate | 1 | 2023 | 42 | 0.060 |
Why?
| | Glycocalyx | 1 | 2023 | 23 | 0.060 |
Why?
| | Chondroitin Sulfates | 1 | 2023 | 35 | 0.060 |
Why?
| | Cyclophosphamide | 1 | 2024 | 222 | 0.060 |
Why?
| | Mice | 1 | 2020 | 15528 | 0.060 |
Why?
| | Cranial Irradiation | 1 | 2023 | 70 | 0.060 |
Why?
| | Mitochondrial Diseases | 1 | 2024 | 79 | 0.060 |
Why?
| | Adipose Tissue, Brown | 1 | 2023 | 71 | 0.060 |
Why?
| | Health Behavior | 1 | 2019 | 720 | 0.060 |
Why?
| | Proteoglycans | 1 | 2023 | 109 | 0.060 |
Why?
| | Fluorodeoxyglucose F18 | 1 | 2023 | 131 | 0.060 |
Why?
| | Respiratory System | 1 | 2023 | 141 | 0.050 |
Why?
| | Threonine | 1 | 2022 | 45 | 0.050 |
Why?
| | Body Mass Index | 2 | 2021 | 2092 | 0.050 |
Why?
| | Systemic Inflammatory Response Syndrome | 1 | 2022 | 75 | 0.050 |
Why?
| | Positron-Emission Tomography | 1 | 2023 | 298 | 0.050 |
Why?
| | Cerebrospinal Fluid | 1 | 2022 | 93 | 0.050 |
Why?
| | Serine | 1 | 2022 | 138 | 0.050 |
Why?
| | Glycine | 1 | 2022 | 162 | 0.050 |
Why?
| | Morbidity | 1 | 2022 | 296 | 0.050 |
Why?
| | Leukocytes | 1 | 2022 | 290 | 0.050 |
Why?
| | Disease Outbreaks | 1 | 2023 | 322 | 0.050 |
Why?
| | Health Resources | 1 | 2022 | 132 | 0.050 |
Why?
| | Photoplethysmography | 1 | 2020 | 19 | 0.050 |
Why?
| | Proof of Concept Study | 1 | 2020 | 46 | 0.050 |
Why?
| | Vital Signs | 1 | 2020 | 42 | 0.050 |
Why?
| | Sleep Apnea Syndromes | 1 | 2021 | 80 | 0.050 |
Why?
| | Automation | 1 | 2020 | 77 | 0.040 |
Why?
| | Perioperative Care | 1 | 2021 | 132 | 0.040 |
Why?
| | Risk Assessment | 1 | 2019 | 3057 | 0.040 |
Why?
| | Tumor Microenvironment | 1 | 2022 | 454 | 0.040 |
Why?
| | Middle Aged | 2 | 2019 | 27627 | 0.040 |
Why?
| | Pulmonary Valve | 1 | 2020 | 99 | 0.040 |
Why?
| | Surveys and Questionnaires | 1 | 2020 | 4709 | 0.040 |
Why?
| | Amino Acids | 1 | 2022 | 465 | 0.040 |
Why?
| | Animals | 1 | 2020 | 33399 | 0.040 |
Why?
| | Inflammation | 1 | 2019 | 2571 | 0.040 |
Why?
| | Accidents, Traffic | 1 | 2019 | 178 | 0.040 |
Why?
| | RNA | 1 | 2023 | 833 | 0.040 |
Why?
| | Overweight | 1 | 2021 | 502 | 0.040 |
Why?
| | Critical Illness | 1 | 2022 | 663 | 0.040 |
Why?
| | Kidney | 1 | 2024 | 1357 | 0.030 |
Why?
| | Pilot Projects | 1 | 2021 | 1420 | 0.030 |
Why?
| | Regression Analysis | 1 | 2019 | 984 | 0.030 |
Why?
| | Chronic Disease | 1 | 2022 | 1637 | 0.030 |
Why?
| | Hospitalization | 1 | 2022 | 1785 | 0.030 |
Why?
| | Models, Educational | 1 | 2014 | 99 | 0.030 |
Why?
| | Statistics, Nonparametric | 1 | 2014 | 403 | 0.030 |
Why?
| | Emergency Service, Hospital | 1 | 2020 | 1864 | 0.020 |
Why?
| | Curriculum | 1 | 2014 | 910 | 0.020 |
Why?
|
|
Miller's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|